Source comparison
Tesamorelin Not Working: Clinical vs User Expectations Comparison
Time to Noticeable VAT Reduction 12–16 weeks at therapeutic dose 4–6 weeks Visceral adipose tissue mobilization is gradual. Subcutaneous fat visibility changes lag behind internal VAT reduction by 8+ weeks Dosing Consistency Daily evening injections without mi
This comparison does not assign a generated winner or score.
- Time to Noticeable VAT Reduction
- 12–16 weeks at therapeutic dose
- 4–6 weeks
- Visceral adipose tissue mobilization is gradual. Subcutaneous fat visibility changes lag behind internal VAT reduction by 8+ weeks
- Dosing Consistency
- Daily evening injections without missed doses
- Sporadic or "as-needed" dosing
- Tesamorelin's 45-minute half-life requires daily administration to maintain pituitary sensitization
- Storage Protocol
- Lyophilised powder at −20°C; reconstituted solution at 2–8°C continuously
- Room-temperature storage for "a few hours" or refrigerator door placement
- Any temperature excursion above 8°C for >6 hours risks irreversible protein denaturation
- Reconstitution Technique
- Slow injection down vial wall; passive dissolution; no shaking
- Direct injection onto powder; vigorous shaking to "mix faster"
- Mechanical stress from shaking can reduce potency by 20–30% before first use
- Expected VAT Reduction
- 15.2% mean reduction at 26 weeks (HERA study)
- Visible abdominal fat loss within 30 days
- VAT is internal. Subcutaneous changes are secondary and delayed
- Professional Assessment
- Protocol adherence determines outcome more than peptide potency in 68% of reported failures
- Peptide quality is assumed to be the issue
- Most "non-responders" have execution errors, not peptide failures